PT 112

Drug Profile

PT 112

Alternative Names: PT-112

Latest Information Update: 14 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ohio University
  • Developer National Cheng Kung University; Phosplatin Therapeutics; Sarah Cannon Research Institute; SciClone Pharmaceuticals; University of Colorado at Colorado Springs; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Phosphoric acid esters; Platinum complexes; Small molecules
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Multiple myeloma; Solid tumours

Most Recent Events

  • 26 Feb 2018 SciClone Pharmaceuticals plans a phase I/II trial for Solid Tumours (Monotherapy; Metastatic disease; Late stage disease) (IV) (NCT03439761)
  • 07 Feb 2018 PT 112 receives Orphan Drug status for Multiple myeloma in USA
  • 30 Jan 2018 Phosplatin Therapeutics, Pfizer and EMD Serono plans the phase I/II PAVE-1 trial for Solid tumours (Late-stage disease, Combination therapy, Metastatic disease) in USA (NCT03409458)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top